Hologic, Inc. Logo

Hologic, Inc.

HOLX

(1.2)
Stock Price

82,16 USD

9.18% ROA

10.22% ROE

39.09x PER

Market Cap.

17.450.618.130,00 USD

56.17% DER

0% Yield

15.93% NPM

Hologic, Inc. Stock Analysis

Hologic, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hologic, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 ROE

The stock's ROE falls within an average range (9.47%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

3 ROA

The stock's ROA (9.49%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

4 DER

The stock maintains a fair debt to equity ratio (54%), indicating a reasonable balance between the money it owes and the ownership it possesses.

5 PBV

The stock's elevated P/BV ratio (3.42x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-88) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Hologic, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hologic, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Hologic, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hologic, Inc. Revenue
Year Revenue Growth
1989 11.400.000
1990 19.800.000 42.42%
1991 17.100.000 -15.79%
1992 26.200.000 34.73%
1993 24.800.000 -5.65%
1994 38.500.000 35.58%
1995 43.400.000 11.29%
1996 88.200.000 50.79%
1997 106.700.000 17.34%
1998 115.600.000 7.7%
1999 84.100.000 -37.46%
2000 93.746.000 10.29%
2001 178.491.000 47.48%
2002 190.192.000 6.15%
2003 204.035.000 6.78%
2004 228.705.000 10.79%
2005 287.684.000 20.5%
2006 462.680.000 37.82%
2007 738.368.000 37.34%
2008 1.674.499.000 55.91%
2009 1.637.134.000 -2.28%
2010 1.679.552.000 2.53%
2011 1.789.349.000 6.14%
2012 2.002.652.000 10.65%
2013 2.492.279.000 19.65%
2014 2.530.700.000 1.52%
2015 2.705.000.000 6.44%
2016 2.832.700.000 4.51%
2017 3.058.800.000 7.39%
2018 3.217.900.000 4.94%
2019 3.367.300.000 4.44%
2020 3.776.400.000 10.83%
2021 5.632.300.000 32.95%
2022 4.862.800.000 -15.82%
2023 3.781.200.000 -28.6%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hologic, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 3.400.000 100%
1995 4.300.000 20.93%
1996 0 0%
1997 8.500.000 100%
1998 9.800.000 13.27%
1999 12.700.000 22.83%
2000 17.178.000 26.07%
2001 23.328.000 26.36%
2002 20.362.000 -14.57%
2003 18.381.000 -10.78%
2004 16.659.000 -10.34%
2005 18.617.000 10.52%
2006 28.294.000 34.2%
2007 44.484.000 36.4%
2008 81.421.000 45.37%
2009 94.328.000 13.68%
2010 104.305.000 9.57%
2011 116.696.000 10.62%
2012 130.962.000 10.89%
2013 197.646.000 33.74%
2014 203.200.000 2.73%
2015 214.900.000 5.44%
2016 232.100.000 7.41%
2017 232.800.000 0.3%
2018 218.700.000 -6.45%
2019 232.200.000 5.81%
2020 222.500.000 -4.36%
2021 276.300.000 19.47%
2022 283.400.000 2.51%
2023 291.600.000 2.81%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hologic, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 148.825.000 100%
2010 159.743.000 6.83%
2011 158.793.000 -0.6%
2012 220.042.000 27.84%
2013 227.680.000 3.35%
2014 259.800.000 12.36%
2015 261.000.000 0.46%
2016 267.300.000 2.36%
2017 343.300.000 22.14%
2018 366.100.000 6.23%
2019 332.300.000 -10.17%
2020 356.000.000 6.66%
2021 433.200.000 17.82%
2022 407.700.000 -6.25%
2023 371.600.000 -9.71%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hologic, Inc. EBITDA
Year EBITDA Growth
1989 1.700.000
1990 2.800.000 39.29%
1991 -300.000 1033.33%
1992 800.000 137.5%
1993 -1.900.000 142.11%
1994 4.500.000 142.22%
1995 7.500.000 40%
1996 8.100.000 7.41%
1997 18.500.000 56.22%
1998 7.400.000 -150%
1999 -5.600.000 232.14%
2000 -17.712.000 68.38%
2001 -7.035.000 -151.77%
2002 13.773.000 151.08%
2003 10.430.000 -32.05%
2004 20.175.000 48.3%
2005 40.205.000 49.82%
2006 101.179.000 60.26%
2007 178.914.000 43.45%
2008 1.122.689.000 84.06%
2009 376.517.000 -198.18%
2010 226.494.000 -66.24%
2011 490.362.000 53.81%
2012 327.923.000 -49.54%
2013 397.530.000 17.51%
2014 447.200.000 11.11%
2015 965.300.000 53.67%
2016 1.051.800.000 8.22%
2017 949.700.000 -10.75%
2018 1.002.200.000 5.24%
2019 597.500.000 -67.73%
2020 1.514.100.000 60.54%
2021 2.885.800.000 47.53%
2022 2.104.700.000 -37.11%
2023 1.222.000.000 -72.23%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hologic, Inc. Gross Profit
Year Gross Profit Growth
1989 7.300.000
1990 10.600.000 31.13%
1991 8.900.000 -19.1%
1992 13.000.000 31.54%
1993 11.500.000 -13.04%
1994 18.200.000 36.81%
1995 21.900.000 16.89%
1996 47.800.000 54.18%
1997 60.500.000 20.99%
1998 61.600.000 1.79%
1999 37.300.000 -65.15%
2000 34.562.000 -7.92%
2001 62.314.000 44.54%
2002 71.816.000 13.23%
2003 73.580.000 2.4%
2004 85.369.000 13.81%
2005 113.025.000 24.47%
2006 193.532.000 41.6%
2007 345.567.000 44%
2008 892.518.000 61.28%
2009 857.486.000 -4.09%
2010 736.638.000 -16.41%
2011 923.181.000 20.21%
2012 994.437.000 7.17%
2013 1.161.388.000 14.38%
2014 1.245.500.000 6.75%
2015 1.432.700.000 13.07%
2016 1.563.300.000 8.35%
2017 1.621.000.000 3.56%
2018 1.696.700.000 4.46%
2019 1.308.100.000 -29.71%
2020 2.227.500.000 41.27%
2021 3.795.800.000 41.32%
2022 2.997.400.000 -26.64%
2023 2.001.200.000 -49.78%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hologic, Inc. Net Profit
Year Net Profit Growth
1989 1.400.000
1990 2.600.000 46.15%
1991 700.000 -271.43%
1992 1.500.000 53.33%
1993 -1.800.000 183.33%
1994 3.000.000 160%
1995 1.900.000 -57.89%
1996 11.400.000 83.33%
1997 17.700.000 35.59%
1998 10.400.000 -70.19%
1999 -3.700.000 381.08%
2000 -18.619.000 80.13%
2001 -20.850.000 10.7%
2002 179.000 11748.04%
2003 2.882.000 93.79%
2004 12.164.000 76.31%
2005 28.256.000 56.95%
2006 27.423.000 -3.04%
2007 94.578.000 71%
2008 -385.617.000 124.53%
2009 -2.176.237.000 82.28%
2010 -62.813.000 -3364.63%
2011 157.150.000 139.97%
2012 -73.634.000 313.42%
2013 -1.172.838.000 93.72%
2014 17.300.000 6879.41%
2015 131.600.000 86.85%
2016 330.800.000 60.22%
2017 755.500.000 56.21%
2018 -111.300.000 778.8%
2019 -40.200.000 -176.87%
2020 1.115.200.000 103.6%
2021 1.871.500.000 40.41%
2022 1.302.000.000 -43.74%
2023 362.400.000 -259.27%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hologic, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 -2 100%
2009 -8 87.5%
2010 0 0%
2011 1 0%
2012 0 0%
2013 -4 100%
2014 0 0%
2015 0 0%
2016 1 100%
2017 3 50%
2018 0 0%
2019 0 0%
2020 4 100%
2021 7 42.86%
2022 5 -40%
2023 1 -400%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hologic, Inc. Free Cashflow
Year Free Cashflow Growth
1991 -1.600.000
1992 -900.000 -77.78%
1993 -500.000 -80%
1994 -3.500.000 85.71%
1995 700.000 600%
1996 -1.300.000 153.85%
1997 10.500.000 112.38%
1998 -8.000.000 231.25%
1999 -6.600.000 -21.21%
2000 -6.498.000 -1.57%
2001 -14.581.000 55.44%
2002 823.000 1871.69%
2003 -3.415.000 124.1%
2004 18.695.000 118.27%
2005 36.674.000 49.02%
2006 -9.459.000 487.72%
2007 130.410.000 107.25%
2008 311.312.000 58.11%
2009 480.662.000 35.23%
2010 404.232.000 -18.91%
2011 392.018.000 -3.12%
2012 286.949.000 -36.62%
2013 403.692.000 28.92%
2014 428.200.000 5.72%
2015 696.700.000 38.54%
2016 688.700.000 -1.16%
2017 -99.300.000 793.55%
2018 627.300.000 115.83%
2019 535.900.000 -17.06%
2020 740.200.000 27.6%
2021 2.167.700.000 65.85%
2022 1.998.500.000 -8.47%
2023 206.200.000 -869.2%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hologic, Inc. Operating Cashflow
Year Operating Cashflow Growth
1991 -1.200.000
1992 -400.000 -200%
1993 -300.000 -33.33%
1994 -3.000.000 90%
1995 1.500.000 300%
1996 1.100.000 -36.36%
1997 12.600.000 91.27%
1998 14.600.000 13.7%
1999 2.300.000 -534.78%
2000 -677.000 439.73%
2001 -10.251.000 93.4%
2002 6.961.000 247.26%
2003 4.731.000 -47.14%
2004 25.882.000 81.72%
2005 44.373.000 41.67%
2006 31.124.000 -42.57%
2007 153.250.000 79.69%
2008 364.596.000 57.97%
2009 546.365.000 33.27%
2010 456.712.000 -19.63%
2011 456.024.000 -0.15%
2012 370.222.000 -23.18%
2013 493.822.000 25.03%
2014 508.400.000 2.87%
2015 786.100.000 35.33%
2016 787.200.000 0.14%
2017 8.300.000 -9384.34%
2018 732.900.000 98.87%
2019 649.500.000 -12.84%
2020 896.600.000 27.56%
2021 2.330.400.000 61.53%
2022 2.125.700.000 -9.63%
2023 258.700.000 -721.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hologic, Inc. Capital Expenditure
Year Capital Expenditure Growth
1991 400.000
1992 500.000 20%
1993 200.000 -150%
1994 500.000 60%
1995 800.000 37.5%
1996 2.400.000 66.67%
1997 2.100.000 -14.29%
1998 22.600.000 90.71%
1999 8.900.000 -153.93%
2000 5.821.000 -52.89%
2001 4.330.000 -34.43%
2002 6.138.000 29.46%
2003 8.146.000 24.65%
2004 7.187.000 -13.34%
2005 7.699.000 6.65%
2006 40.583.000 81.03%
2007 22.840.000 -77.68%
2008 53.284.000 57.14%
2009 65.703.000 18.9%
2010 52.480.000 -25.2%
2011 64.006.000 18.01%
2012 83.273.000 23.14%
2013 90.130.000 7.61%
2014 80.200.000 -12.38%
2015 89.400.000 10.29%
2016 98.500.000 9.24%
2017 107.600.000 8.46%
2018 105.600.000 -1.89%
2019 113.600.000 7.04%
2020 156.400.000 27.37%
2021 162.700.000 3.87%
2022 127.200.000 -27.91%
2023 52.500.000 -142.29%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hologic, Inc. Equity
Year Equity Growth
1989 100.000
1990 15.700.000 99.36%
1991 16.700.000 5.99%
1992 18.100.000 7.73%
1993 16.300.000 -11.04%
1994 19.900.000 18.09%
1995 22.700.000 12.33%
1996 107.300.000 78.84%
1997 126.800.000 15.38%
1998 140.400.000 9.69%
1999 150.400.000 6.65%
2000 131.572.000 -14.31%
2001 111.807.000 -17.68%
2002 142.409.000 21.49%
2003 148.927.000 4.38%
2004 166.275.000 10.43%
2005 217.834.000 23.67%
2006 605.750.000 64.04%
2007 805.723.000 24.82%
2008 4.642.269.000 82.64%
2009 2.512.715.000 -84.75%
2010 2.698.549.000 6.89%
2011 2.936.895.000 8.12%
2012 2.961.031.000 0.82%
2013 1.941.513.000 -52.51%
2014 2.063.000.000 5.89%
2015 2.079.200.000 0.78%
2016 2.142.700.000 2.96%
2017 2.784.700.000 23.05%
2018 2.428.800.000 -14.65%
2019 2.279.100.000 -6.57%
2020 2.707.300.000 15.82%
2021 4.218.600.000 35.82%
2022 4.876.200.000 13.49%
2023 5.016.900.000 2.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hologic, Inc. Assets
Year Assets Growth
1989 5.400.000
1990 20.300.000 73.4%
1991 19.800.000 -2.53%
1992 22.700.000 12.78%
1993 22.200.000 -2.25%
1994 28.500.000 22.11%
1995 33.900.000 15.93%
1996 123.100.000 72.46%
1997 144.700.000 14.93%
1998 172.600.000 16.16%
1999 175.800.000 1.82%
2000 219.655.000 19.97%
2001 195.119.000 -12.57%
2002 184.275.000 -5.88%
2003 188.603.000 2.29%
2004 211.751.000 10.93%
2005 279.839.000 24.33%
2006 856.205.000 67.32%
2007 1.066.349.000 19.71%
2008 8.134.632.000 86.89%
2009 5.689.828.000 -42.97%
2010 5.625.834.000 -1.14%
2011 6.008.780.000 6.37%
2012 10.477.108.000 42.65%
2013 9.000.823.000 -16.4%
2014 8.414.700.000 -6.97%
2015 7.670.100.000 -9.71%
2016 7.317.000.000 -4.83%
2017 7.979.600.000 8.3%
2018 7.230.900.000 -10.35%
2019 6.611.100.000 -9.38%
2020 7.195.800.000 8.13%
2021 8.919.900.000 19.33%
2022 9.071.200.000 1.67%
2023 9.139.300.000 0.75%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hologic, Inc. Liabilities
Year Liabilities Growth
1989 5.300.000
1990 4.600.000 -15.22%
1991 3.100.000 -48.39%
1992 4.600.000 32.61%
1993 5.900.000 22.03%
1994 8.600.000 31.4%
1995 11.200.000 23.21%
1996 15.800.000 29.11%
1997 17.900.000 11.73%
1998 32.200.000 44.41%
1999 25.400.000 -26.77%
2000 88.083.000 71.16%
2001 83.312.000 -5.73%
2002 41.866.000 -99%
2003 39.676.000 -5.52%
2004 45.476.000 12.75%
2005 62.005.000 26.66%
2006 250.455.000 75.24%
2007 260.626.000 3.9%
2008 3.492.363.000 92.54%
2009 3.177.113.000 -9.92%
2010 2.927.285.000 -8.53%
2011 3.071.885.000 4.71%
2012 7.516.077.000 59.13%
2013 7.059.310.000 -6.47%
2014 6.351.700.000 -11.14%
2015 5.590.900.000 -13.61%
2016 5.174.300.000 -8.05%
2017 5.194.900.000 0.4%
2018 4.802.100.000 -8.18%
2019 4.332.000.000 -10.85%
2020 4.488.500.000 3.49%
2021 4.701.300.000 4.53%
2022 4.195.000.000 -12.07%
2023 4.122.400.000 -1.76%

Hologic, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
16.44
Net Income per Share
1.86
Price to Earning Ratio
39.09x
Price To Sales Ratio
4.33x
POCF Ratio
16.96
PFCF Ratio
19.37
Price to Book Ratio
3.55
EV to Sales
4.35
EV Over EBITDA
14.58
EV to Operating CashFlow
16.69
EV to FreeCashFlow
19.47
Earnings Yield
0.03
FreeCashFlow Yield
0.05
Market Cap
17,45 Bil.
Enterprise Value
17,55 Bil.
Graham Number
29.27
Graham NetNet
-2.54

Income Statement Metrics

Net Income per Share
1.86
Income Quality
2.31
ROE
0.09
Return On Assets
0.06
Return On Capital Employed
0.08
Net Income per EBT
0.82
EBT Per Ebit
1.04
Ebit per Revenue
0.19
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.62
Operating Profit Margin
0.19
Pretax Profit Margin
0.19
Net Profit Margin
0.16

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
4.29
Free CashFlow per Share
3.68
Capex to Operating CashFlow
-0.14
Capex to Revenue
-0.04
Capex to Depreciation
-0.46
Return on Invested Capital
0.06
Return on Tangible Assets
0.09
Days Sales Outstanding
56.66
Days Payables Outstanding
132.83
Days of Inventory on Hand
115.08
Receivables Turnover
6.44
Payables Turnover
2.75
Inventory Turnover
3.17
Capex per Share
-0.61

Balance Sheet

Cash per Share
11,11
Book Value per Share
20,47
Tangible Book Value per Share
20.47
Shareholders Equity per Share
20.47
Interest Debt per Share
11.95
Debt to Equity
0.56
Debt to Assets
0.31
Net Debt to EBITDA
0.08
Current Ratio
3.47
Tangible Asset Value
0,85 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
0.56
Working Capital
2,98 Bil.
Intangibles to Total Assets
0.46
Average Receivables
0,66 Bil.
Average Payables
0,45 Bil.
Average Inventory
648850000
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hologic, Inc. Dividends
Year Dividends Growth

Hologic, Inc. Profile

About Hologic, Inc.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

CEO
Mr. Stephen P. MacMillan
Employee
6.990
Address
250 Campus Drive
Marlborough, 01752

Hologic, Inc. Executives & BODs

Hologic, Inc. Executives & BODs
# Name Age
1 Ms. Monica Aguirre Berthelot
Vice President & Chief of Staff
70
2 Mr. John M. Griffin
General Counsel
70
3 Ryan M. Simon
Vice President of Investor Relations
70
4 Ms. Karleen M. Oberton
Chief Financial Officer
70
5 Mr. Paul Malenchini
Chief Information Officer
70
6 Mr. Stephen P. MacMillan
Chairman, Chief Executive Officer & President
70
7 Mr. Erik S. Anderson
Division President of Breast & Skeletal Health Solutions
70
8 Mr. Essex D. Mitchell
Chief Operating Officer
70
9 Mr. Peter P. Dunne
Senior Vice President of Human Resources
70
10 Mr. Jan Verstreken
Group President of International
70

Hologic, Inc. Competitors